T Allen, F Zhang, SA Moodie, LE Clemens, A Smith, F … - Diabetes, 2006 - Am Diabetes Assoc Halofenate has been shown previously to lower triglycerides in dyslipidemic subjects. In
addition, significant decreases in fasting plasma glucose were observed but only in type 2 diabetic
patients. We hypothesized that halofenate might be an insulin sensitizer, and we present ... Cited by 38 - Related articles - BL Direct - All 9 versions
T Allen, F Zhang, SA Moodie, LE Clemens, A Smith, F … - 糖尿病学杂志, 2006 - journal.shouxi.net Halofenate has been shown previously to lower triglycerides in dyslipidemic subjects. In
addition, significant decreases in fasting plasma glucose were observed but only in type 2 diabetic
patients. We hypothesized that halofenate might be an insulin sensitizer, and we present ... Related articles - Cached
KR Kim, JH Lee, SJ Kim, SD Rhee, WH Jung, SD … - Biochemical …, 2006 - Elsevier The nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ) is the target for the
anti-diabetic drugs including thiazolidinediones. We report here the identification and characterization
of a novel PPARγ agonist KR-62980. KR-62980 acted as a selective PPARγ agonist in ... Cited by 21 - Related articles - All 6 versions
- ►endojournals.org E Burgermeister, A Schnoebelen, A Flament, J … - Molecular …, 2006 - Endocrine Soc Partial agonists of peroxisome proliferator-activated receptor- (PPAR ), also termed selective
PPAR modulators, are expected to uncouple insulin sensitization from triglyceride (TG) storage
in patients with type 2 diabetes mellitus. These agents shall thus avoid adverse effects, ... Cited by 56 - Related articles - BL Direct - All 4 versions
F Zhang, BE Lavan, FM Gregoire… - PPAR research, 2007 - hindawi.com Page 1. Hindawi Publishing Corporation PPAR Research Volume 2007, Article ID 32696,
7 pages doi:10.1155/2007/32696 Review Article Selective Modulators of PPAR-γ Activity:
Molecular Aspects Related to Obesity and Side-Effects ... Cited by 38 - Related articles - View as HTML - All 10 versions
JJ Acton, RM Black, AB Jones, DE Moller, L Colwell … - Bioorganic & medicinal …, 2005 - Elsevier Non-insulin dependent or Type 2 diabetes mellitus (T2DM) affects a significant number of people
in the industrialized world, and is expected to be a growing medical concern as the post-World
War II generation ages. Onset of T2DM most often occurs in middle age, but younger ... Cited by 27 - Related articles - All 4 versions
K Liu, RM Black, JJ Acton, R Mosley, S Debenham, … - Bioorganic & medicinal …, 2005 - Elsevier The peroxisome proliferator-activated receptor gamma (PPARγ) is member of a large family of
ligand activated nuclear transcription factors. Both rosiglitazone and pioglitazone are full agonists
that specifically activate PPARγ and are used to treat type 2 diabetes (T2DM). 1 However, ... Cited by 29 - Related articles - All 4 versions
BG Shearer, AN Billin - BBA-Molecular and Cell Biology of Lipids, 2007 - Elsevier The peroxisome proliferator-activated receptors (PPARs) are ligand activated transcription factors
belonging to the nuclear receptor superfamily [1]. Three distinct receptor subtypes, PPARα, PPARγ
and PPARβ(δ), have been identified and cloned. While the PPAR subtypes share a high ... Cited by 25 - Related articles - All 4 versions
MC Carmona, K Louche, B Lefebvre, A Pilon, N … - Diabetes, 2007 - Am Diabetes Assoc RESULTS—S 26948 displayed pharmacological features of a high selective ligand for PPARγ
with low potency in promoting adipocyte differentiation. It also displayed a different coactivator
recruitment profile compared with rosiglitazone, being unable to recruit DRIP205 or ... Cited by 8 - Related articles - BL Direct - All 4 versions
